PLANTATION, Fla., Nov. 2 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) today announced that the Company is scheduled to make a
presentation at BIO-Europe 2005, the premier European biotechnology partnering
conference of the year, to be held in Dresden, Germany November 7-9.
Presentation details are as follows:
* Event: 11th Annual BIO-Europe 2005 Partnering Conference
Presenter: Charles A. Rice, President & CEO
When: Tuesday, November 8 at 9:45 a.m. (Germany)
Where: Room #2, Level 4
Mr. Rice will provide updates on the pending registration of Multiferon(R)
in Sweden for first-line adjuvant treatment of high-risk malignant melanoma
patients, plus outline the European strategy for this important indication. In
addition, the presentation will include a review of the Avian Transgenic
Biomanufacturing program and the Company's anti-cancer antibody projects.
"We believe the Multiferon(R) clinical data we submitted to the Swedish
regulatory authorities is unprecedented in terms of the overall survival
benefit for high-risk skin cancer patients, and we anticipate a decision this
year," stated Mr. Rice. "We expect this important approval will be a key step
to implement our strategy for registration in the broader European markets."
BIO-Europe 2005 comprises the penultimate BIO organization meeting of the
calendar year with an expected record turnout of biotech and pharmaceutical
companies. The conference includes two days of pre-scheduled partnering
meetings, which is also expected to draw record participation.
About Viragen, Inc.:
With global operations in the U.S., Scotland and Sweden, Viragen is a
biotechnology company engaged in the research, development, manufacture and
commercialization of pharmaceutical proteins for the treatment of viral
diseases and cancers. Our product portfolio includes: Multiferon(R) (multi-
subtype, natural human alpha interferon) targeting a broad range of infectious
and malignant diseases; and humanized monoclonal antibodies targeting specific
antigens over-expressed on many types of cancers. We are also pioneering the
development of Avian Transgenic Technology, with the renowned Roslin
Institute, as a revolutionary manufacturing platform for the large-scale,
efficient and economical production of human therapeutic proteins and
antibodies.
Viragen is publicly traded on the American Stock Exchange (VRA).
Viragen's majority-owned subsidiary, Viragen International, Inc., is publicly
traded on the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners
include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, Cancer
Research Technology UK, Oxford BioMedica Plc, University of Nottingham (U.K.),
America's Blood Centers and the German Red Cross.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect," "potential,"
"suggests," "may," "should," "could" or similar expressions. Such forward-
looking statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
